2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106123
    Pomisartan 144702-17-0 98%
    Pomisartan is an orally active angiotensin II receptor type AT1 antagonist (IC50=0.26 μM). Pomisartan works by inhibiting the binding of angiotensin II to the AT1 receptor, thereby blocking the vasoconstriction and aldosterone release caused by this interaction. Pomisartan results in a blood pressure-lowering effect.
    Pomisartan
  • HY-106131
    RSD-921 114419-77-1 98%
    RSD-921 (PD-123497) is a potent Na+ channel blocker with anti-arrhythmic activity. RSD-921 displays a low affinity for κ-opioid receptors and behaves as a weak κ-agonist in vitro. RSD 921 displays state-, time- and voltage-dependent block of the open state of cardiac, skeletal muscle and neuronal Na+ channels expressed in Xenopus oocytes. RSD-921 can be used for cardiac arrhythmias research.
    RSD-921
  • HY-106156
    Allotrap 07 151232-75-6 98%
    Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival.
    Allotrap 07
  • HY-106193
    RC-552 253119-91-4 98%
    RC-552 is a novel synthetic glycolipid related in chemical structure to MLA. RC-552 induces delayed cardioprotective effects via an iNOS-dependent pathway. RC-552 attenuates myocardial stunning.
    RC-552
  • HY-106206
    AL-6598 170291-06-2 98%
    AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research.
    AL-6598
  • HY-106207
    Celivarone 401925-43-7 98%
    Celivarone (SSR149744C) is a orally active noniodinated benzofuran derivative with antiarrhythmic properties. Celivarone has the potential for atrial fibrillation and in ventricular arrhythmias research.
    Celivarone
  • HY-106234
    ZP 120C 383123-18-0 98%
    ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia.
    ZP 120C
  • HY-106300
    AA 193 107804-48-8 98%
    AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia.
    AA 193
  • HY-106337
    SB 247083 188186-61-0 98%
    SB 247083 is a selective, competitive and orally active endothelin-A receptor antagonist with a Ki of 0.41 nM. SB 247083 shows a Ki of 467 nM to endothelin-B receptor. SB 247083 shows a Kb of 3.5 nM for ET-1-induced contraction of rat aorta. SB 247083 can be used for the research of cardiovascular disease.
    SB 247083
  • HY-106394
    TP-9201 138297-15-1 98%
    TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC50 = 1-3 μM), while showing lower activity in rabbits (IC50 = 45 μM) and rats (IC50 = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis.
    TP-9201
  • HY-106398
    MED 27 104333-87-1 98%
    MED 27 is an inhibitor of thromboxane synthase and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of Acetylsalicylic acid (HY-14654).
    MED 27
  • HY-106404
    RPR 130737 205054-36-0 98%
    RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis.
    RPR 130737
  • HY-106416
    Neldazosin 109713-79-3 98%
    Neldazosin is a potent alpha1-adrenoceptor antagonist.
    Neldazosin
  • HY-106427
    SA-13353 379262-36-9 98%
    SA-13353 is a TRPV1 agonist with cardioprotective effect. SA-13353 can be used for the research of cardiovascular disease .
    SA-13353
  • HY-106428
    Icrocaptide 169543-49-1 98%
    Icrocaptide (ITF1697) is a stable Lys-Pro-containing peptide that inhibits the intracellular Ca2+-dependent fusion of Weibel-Palade bodies with the plasma membrane. Icrocaptide exerts its activity at the early stages of endothelial activation and inhibits P-selectin and von Willebrand factor secretion. Icrocaptide can be used for the study of a variety of microvascular disorders.
    Icrocaptide
  • HY-106458
    Niludipine 22609-73-0 98%
    Niludipine (Bay a 7168) is an orally active calcium channel blocker and vasodilator with antihypertensive effects. Niludipine can improve early fatal ventricular arrhythmias induced by acute myocardial ischemia in rats. Niludipine can reduce left ventricular systolic and diastolic loads during pacing-induced angina pectoris. Niludipine can be used in the research of cardiovascular diseases such as coronary heart disease and myocardial ischemia.
    Niludipine
  • HY-106468
    Bornaprolol 66451-06-7 98%
    Bornaprolol (FM-24) is a β-adrenoceptor antagonist. Bornaprolol significantly depresses plasma levels of luteinizing hormone (LH) in orchidectomized rat models. Bornaprolol can be used for cardiovascular diseases like hypertension and angina pectoris research.
    Bornaprolol
  • HY-106471
    Pildralazine 64000-73-3 98%
    Pildralazine (Propyldazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model.
    Pildralazine
  • HY-106476
    Primidolol 67227-55-8 98%
    Primidolol (UK-11443), derived from Parmotrema perlatum, possesses antibacterial and antioxidant activities. Primidolol is also an orally active α/β Adrenergic Receptor blocker with antihypertensive activity. Primidolol can be used in research related to infections and cardiovascular diseases.
    Primidolol
  • HY-106499
    Sulfinalol 66264-77-5 98%
    Sulfinalol is an orally active β-adrenoceptor antagonist with direct vasodilator activity.
    Sulfinalol
Cat. No. Product Name / Synonyms Application Reactivity